

MIRA INFORM REPORT

Report No. :	532659
Report Date :	03.10.2018

IDENTIFICATION DETAILS

Name :	MOLECLAR CLEANING LABORATORIES MCLAB LLC
Registered Office :	Agent for Service of Process: Changping Shi 100 Miraloma Dr San Francisco Ca 94127
Country :	United States
Financials (as on) :	2017 (Summarized)
Year of Establishment :	1998
Legal Form :	Domestic Limited Liability Company
Line of Business :	<ul style="list-style-type: none"> • Biotechnology Research Services. • Subject line of business includes providing commercial physical and biological research and development. The company provides a selection of molecular biology related products, including antibodies, biochemical reagents, cloning kits, enzymes, PCR kits, protein gels & solutions and more.
No. of Employees :	11

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	B
------------------------	---

Credit Rating	Explanation	Rating Comments
B	Medium Risk	Business dealings permissible on a regular monitoring basis

Status :	Moderate
Payment Behaviour :	Slow
Litigation :	Clear

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

NOTES:

Any query related to this report can be made on e-mail: while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (31.12.2017)	Current Rating (01.04.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

UNITED STATES - ECONOMIC OVERVIEW

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

The Federal Reserve Board (Fed) announced plans in December 2012 to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA

STATUTORY INFORMATION

Legal Name	Moleclar Cleaning Laboratories Mclab LLC
Trade Name	MCLAB / MCLAB LLC
ID	ID
ID Details	200919010406
Creation Date	1998
Incorporation Date	06/30/2009
Legal Address	Agent for Service of Process: CHANGPING SHI 100 MIRALOMA DR SAN FRANCISCO CA 94127 USA
Operative Address	320 Harbor Way, South San Francisco, CA 94080, U.S.A.
Telephone	Toll Free: 1-888-MCLAB-88 Tel : 1-(650)-871-8771
Fax	1-(650)-871-8796
Legal Form	DOMESTIC LIMITED LIABILITY COMPANY
E-Mail	mclab@mclab.com labsupport@mclab.com
Registered In	CALIFORNIA
Website	www.mclab.com
Contact	Changping Shi, Chief Executive Officer and Founder
Staff	11 employees
Activity	Biotechnology Research Services

BANKS

Name of Bank	Reported Amount
There are not informed banks	
Description	The company does not make its banking data public.

HISTORY

History	The company was founded in 1998
Key Developments	NA
Parent Company	NA

PRINCIPAL ACTIVITY

General Description

Moleclar Cleaning Laboratories McLab LLC's line of business includes providing commercial physical and biological research and development. The company provides a selection of molecular biology related products, including antibodies, biochemical reagents, cloning kits, enzymes, PCR kits, protein gels & solutions and more.

Service/Product Description

PRODUCTS:

Enzymes
Molecular Cloning
PCR
Next-Generation Sequencing
Biochemical Reagents
Gene Editing
Sanger Sequencing and Fragment Analysis
Protein Purification
Nucleic Acid Purification
Recombinant Proteins
Promotional Sale

SERVICES:

Basic DNA Sequencing Services
Specialized DNA Sequencing Services
Antibody Sequencing Service
DNA Services
NGS Services
PCR Cloning and Subcloning
Plasmid Purification Services
qPCR Services
Antibody Services
Cell Line Identification
Protein Services
Capillary Array Services
Wholesale and Retail

Sales

National and International

Operations Area

Imports From

The Netherlands

Export To

There are no export of Moleclar Cleaning Laboratories McLab LLC. However, the company's products are sold through distributors all around the world, including Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Hungary, Greece, India, Israel, Poland, New Zealand, Turkey, United Kingdom and Vietnam

Employees 11 employees
Payments With Suppliers Slow

**BRANDS
Brand**

Comments

There are not informed brands

CLIENTS

Name of Client

Country

Comments

UCSF	USA	NA
PFIZER	USA	NA
USDA	USA	NA
FDA	USA	NA

Comments

The company`s main clients include national companies, international companies and private customers.

SUPPLIERS

Supplier Name

Country

Comments

NIMAGEN B.V	The Netherlands	NA
-------------	-----------------	----

Comments

-

LOCATION

Headquarters 320 Harbor Way, South San Francisco, CA 94080, U.S.A.
Branches No branches found
Industries NA

GROUP STRUCTURE AND SUBDIARY COMPANIES

Listed at the stock exchange NO
Capital NA
Shareholders (%) This is a private company. The company does not disclose information on shareholders. The following

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Management

Subsidiary Companies

Related Companies

information has been obtained through private sources and could not be confirmed:

Major holder is Changping Shi
Changping Shi, Chief Executive Officer and Founder
Fengling Wang, General Manager
NA

Clauning (Beijing) Biotechnology Co., Ltd.
407A, Tianchuang Technology Building, West District,
Zhongguancun, Haidian District, Beijing
Zip code: 100080
China
Contact Person: Gina Shi
Phone: +8610 62698317
Fax: +8610 62698352
Email: icloning@icloning.cn
Website: www.icloning.cn

DISTRIBUTORS:
Nimagen (The Netherlands)
Carolina Biosystems, s.r.o. (Czech Republic)
Gene Target Solutions (Australia)
Agentek (Israel)
DoronScientific (Israel)
Sciencewerke Ptd Ltd (Singapore, Malaysia and Indonesia)

FINANCIAL INFORMATION

General Description

The company does not make its financial statements public. The following information has been provided by private sources:

Year/Currency

2017 USD

Sales

1,500,000

Money Flow

Normal

IMPORT FOB DOLLAR

Year

Amount

There are not Import Fob Dollar informed

EXPORT FOB DOLLAR

Year

Amount

There are not Export Fob Dollar informed

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

LEGAL FILINGS

Trademarks

NANOPOP-7 - Trademark Details
Status: 800 - Registered And Renewed
Image for trademark with serial number 77253711
Serial Number77253711
Registration Number3417840
Word MarkNANOPOP-7
Status800 - Registered And Renewed
Status Date2017-10-08
Filing Date2007-08-13
Registration Number3417840
Registration Date2008-04-29
Mark Drawing4000 - Standard character mark Typeset
Published for Opposition Date2008-02-12
Law Office Assigned Location CodeM20
Employee NameBELLO, ZACHARY R

CARE (CAPILLARY ARRAY REGENERATION
EXCELLENCE) - Trademark Details
Status: 800 - Registered And Renewed
Image for trademark with serial number 77253775
Serial Number77253775
Registration Number3417845
Word MarkCARE (CAPILLARY ARRAY
REGENERATION EXCELLENCE)
Status800 - Registered And Renewed
Status Date2017-10-08
Filing Date2007-08-13
Registration Number3417845
Registration Date2008-04-29
Mark Drawing4000 - Standard character mark Typeset
Published for Opposition Date2008-02-12
Law Office Assigned Location CodeM20
Employee NameBELLO, ZACHARY R

NANOPOP - Trademark Details
Status: 601 - Abandoned - Express
Image for trademark with serial number 85302359
Serial Number85302359
Word MarkNANOPOP
Status601 - Abandoned - Express
Status Date2011-04-29
Filing Date2011-04-22
Mark Drawing4000 - Standard character mark Typeset

Patents Registered

Compositions and Methods for Preparing Sequencing Libraries

Publication number: 20160348152

Abstract: Compositions comprising activated topoisomerase adaptors (TOPO-adaptors) and methods of using the activated TOPO-adaptors are provided for preparing a library of target DNA duplexes derived from sample polynucleotides (e.g., DNA, RNA) for the streamlined preparation of a large number of samples. Such libraries may be used for Next Generation Sequencing (NGS).

Type: Application

Filed: May 26, 2016

Publication date: December 1, 2016

Applicant: Molecular Cloning Laboratories (MCLAB) LLC

Inventors: Jianping Zheng, Changping Shi, Dan Shen, Thang Nguyen

Renewals

Document Type File Date

SI-COMplete 02/09/2017

SI-COMplete 12/30/2015

REGISTRATION 06/30/2009

UCC (Uniform Commercial Code)

No records found

OFAC Sanctions List Search

The company is not listed in the OFAC list.

SUMMARY

Summary

Founded in 1998, Moleclar Cleaning Laboratories McLab LLC's line of business includes providing commercial physical and biological research and development. The company provides a selection of molecular biology related products, including antibodies, biochemical reagents, cloning kits, enzymes, PCR kits, protein gels & solutions and more.

The company has approximately 11 employees and generates an estimated USD 1.5 million in annual revenue.

The company imports from the Netherlands, operating within national and international markets.

The company's products are sold through distributors all around the world, including Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Hungary, Greece, India, Israel, Poland, New

Zealand, Turkey, United Kingdom and Vietnam.

This has been an ACTIVE company incorporated in CALIFORNIA in 2009.

RISK INFORMATION

Debts	Medium
Payments	Slow
Cash Flow	Medium
State	ACTIVE

INTERVIEW

First Name	NA
Position	Scientist
Comments	The person contacted only confirmed name, telephone, website and email, but refused to provide further information through the phone, explaining that he was not authorized to do so. He did not tell us his name.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 72.80
UK Pound	1	INR 94.88
Euro	1	INR 84.38
USD	1	INR 73.07

Note: Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	PRA
Report Prepared by :	NIT

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.